Tarrytown, NY–Regeneron Pharmaceuticals (NASDAQ: REGN) is ramping up its U.S. manufacturing footprint through a major new partnership with FUJIFILM Diosynth Biotechnologies.
The agreement will enable production of Regeneron’s leading biologic medicines at Fujifilm’s cutting-edge facility in Holly Springs, North Carolina, nearly doubling the company’s large-scale U.S. manufacturing capacity.
This 10-year collaboration, with an estimated value exceeding $3 billion, is part of Regeneron’s broader strategic investment of more than $7 billion across New York and North Carolina to bolster drug production, research, and job creation.
“We’ve built our company and our pipeline right here in the U.S., and we’re continuing to expand our capabilities to match the scientific opportunities ahead,” said Dr. Leonard Schleifer, Regeneron’s co-Chair, President and CEO. “This new collaboration supports our commitment to deliver lifesaving medicines while creating high-quality jobs and fueling regional economic growth.”
In addition to the North Carolina initiative, Regeneron is significantly expanding its Tarrytown, NY, headquarters with a $3.6 billion investment that includes new research labs and manufacturing facilities, expected to add 1,000 skilled positions. The company is also building a high-tech fill/finish site in Rensselaer, NY, and has acquired a large facility in Saratoga Springs for future growth.
Daniel Van Plew, EVP and General Manager of Industrial Operations at Regeneron, noted that the partnership with Fujifilm reflects both trust in the company’s capabilities and a shared dedication to excellence. “Our teams are already working to bring the Holly Springs facility online to ensure we can meet growing demand,” he said.
Fujifilm Diosynth CEO Lars Petersen echoed the enthusiasm, calling the partnership “an honor” and a powerful collaboration aimed at delivering critical therapies to patients worldwide.
Over the past five years, Regeneron has added over 7,000 jobs, the majority of which are high-paying roles in R&D and manufacturing across the U.S., further establishing the company as a major force in both biotech innovation and American industry.
